Detalhe da pesquisa
1.
The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injury.
Spinal Cord
; 57(5): 348-359, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30962518
2.
Lower extremity outcome measures: considerations for clinical trials in spinal cord injury.
Spinal Cord
; 56(7): 628-642, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29700477
3.
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Mult Scler
; 21(10): 1322-31, 2015 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-25583832
4.
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.
Stroke
; 44(7): 1942-50, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23652269
5.
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Ann Neurol
; 68(4): 494-502, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20976768
6.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Lancet
; 373(9665): 732-8, 2009 Feb 28.
Artigo
Inglês
| MEDLINE | ID: mdl-19249634
7.
Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Clin Ther
; 31(2): 328-35, 2009 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-19302905
8.
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
CNS Drugs
; 33(1): 61-79, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30535670
9.
Chondroitinase improves anatomical and functional outcomes after primate spinal cord injury.
Nat Neurosci
; 22(8): 1269-1275, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31235933
10.
Miracles and molecules--progress in spinal cord repair.
Nat Neurosci
; 5 Suppl: 1051-4, 2002 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-12403984
11.
4-Aminopyridine: new life for an old drug. Reply.
Ann Neurol
; 69(1): 218-20, 2011 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-21280101
12.
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot Study.
Clin Ther
; 39(2): 337-346, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-28131322
13.
Targeting Translational Successes through CANSORT-SCI: Using Pet Dogs To Identify Effective Treatments for Spinal Cord Injury.
J Neurotrauma
; 34(12): 2007-2018, 2017 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28230415
14.
Clinical trials in spinal cord injury.
J Neurotrauma
; 23(3-4): 586-93, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16629639
15.
4-chloro-3-hydroxyanthranilate reduces local quinolinic acid synthesis, improves functional recovery, and preserves white matter after spinal cord injury.
J Neurotrauma
; 23(6): 866-81, 2006 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-16774472
16.
Experimental Treatments for Spinal Cord Injury: What you Should Know.
Top Spinal Cord Inj Rehabil
; 27(2): 50-74, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34108834
17.
Chondroitinase ABCI improves locomotion and bladder function following contusion injury of the rat spinal cord.
J Neurotrauma
; 22(2): 226-39, 2005 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-15716629
18.
Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Clin Ther
; 37(12): 2780-7, 2015 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26565077
19.
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled Trial.
Int J MS Care
; 17(3): 138-45, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-26052259
20.
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury.
Clin Neuropharmacol
; 26(4): 185-92, 2003.
Artigo
Inglês
| MEDLINE | ID: mdl-12897638